Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
2027. ápr. 9.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
2026. dec. 31.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
2026. nov. 15.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
2026. nov. 11.· PHASE1_PHASE2 · SUSPENDED· CTGOV
Publikáció
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.
2026. nov. 3.· Blood cancer discovery· PUBMED
Publikáció
EML4-ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway.
2026. nov. 2.· Cancer discovery· PUBMED
Publikáció
Expanding the RAS-verse: Novel Inhibitors, Emergent Dependencies, Fresh Opportunities in RAS-Mutant NSCLC.
2026. nov. 2.· Cancer discovery· PUBMED
Publikáció
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-type RAS Isoforms in Codon 13 RAS-Mutant Cancers.
2026. nov. 2.· Cancer discovery· PUBMED
Vizsgálat
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
2026. nov. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
2026. nov. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC.
2026. nov. 1.· Nature reviews. Clinical oncology· PUBMED
Publikáció
Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.
2026. nov. 1.· British journal of cancer· PUBMED
Vizsgálat
A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
2026. okt. 29.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
ACK1 inhibition suppresses topoisomerase IIα, causing DNA damage accumulation and cellular senescence in RAS mutant lung cancer cells.
2026. okt. 28.· Oncogene· PUBMED
Publikáció
Re: "Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer.".
2026. okt. 24.· Asia-Pacific journal of clinical oncology· PUBMED
Publikáció
Response Letter: Re: "Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer".
2026. okt. 22.· Asia-Pacific journal of clinical oncology· PUBMED
Publikáció
Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design.
2026. okt. 22.· Experimental hematology & oncology· PUBMED
Publikáció
Genomic and clinical landscape of RAS mutations in acute myeloid leukemia.
2026. okt. 16.· Blood· PUBMED
Publikáció
Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses.
2026. okt. 16.· Oncogene· PUBMED
Publikáció
RAS pathway mutations orchestrate chromatin reconfiguration and transcriptional rewiring in colorectal cancer.
2026. okt. 14.· Cell communication and signaling : CCS· PUBMED
Publikáció
[Analysis of efficacy and prognostic factors of neoadjuvant chemoradiotherapy in locally advanced mid-low rectal cancer patients with RAS gene mutation].
2026. okt. 13.· Zhonghua yi xue za zhi· PUBMED
Publikáció
Blockade of mutant RAS oncogenic signaling: A 2026 update.
2026. okt. 11.· Pharmacological research· PUBMED
Publikáció
RAS-Pathway Mutation Profiles and Clinical Outcomes Among Patients With Colorectal Cancer.
2026. okt. 1.· Cancer medicine· PUBMED
Publikáció
[Two Cases of Multiple Colorectal Cancer in Which Circulating RAS Mutation Analysis by BEAMing Was Useful for Identifying the Recurrent Primary Lesion].
2026. okt. 1.· Gan to kagaku ryoho. Cancer & chemotherapy· PUBMED
Publikáció
Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia.
2026. szept. 30.· Blood cancer discovery· PUBMED
Publikáció
Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes.
2026. szept. 28.· Experimental hematology & oncology· PUBMED
Publikáció
Efficacy and Safety of Daraxonrasib (RMC-6236) in Previously Treated Metastatic RAS-Mutated Pancreatic Ductal Adenocarcinoma: A Systematic Review.
2026. szept. 25.· Cancers· PUBMED
Preprint
Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.
2026. szept. 18.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
RAS Mutations as Prognostic Biomarkers in Digestive Cancers: From Binary Classification to Variant-Specific and Context-Dependent Risk Stratification.
2026. szept. 16.· Cureus· PUBMED